Breaking News
April 23, 2018 - Eating fish could prevent Parkinson’s disease
April 23, 2018 - Key factor in development of Parkinson’s disease identified
April 23, 2018 - Higher consumption of fish linked to better neurological health
April 23, 2018 - Genevac announces HT Series 3 evaporators with Inert Gas Purge option
April 23, 2018 - Researchers clarify immune response for patients with breast cancer brain metastases
April 23, 2018 - Polypharmacy More Likely for Cancer Survivors
April 23, 2018 - Obesity is shifting cancer to young adults
April 23, 2018 - Scientists illustrate role of novel chromosomal mutations in fosfomycin resistance
April 23, 2018 - Newly developed drug compound may help treat Charcot-Marie-Tooth disease
April 23, 2018 - Marriage Means ‘I Do’ for Skin Cancer Detection
April 23, 2018 - Freezing hunger-signaling nerve may help ignite weight loss
April 23, 2018 - Wear exoskeletons with caution for heavy lifting, researchers say
April 23, 2018 - Research offers new hope for healing wounds in patients with diabetes
April 23, 2018 - Shorter courses of radiotherapy found to be safe, effective for prostate cancer patients
April 23, 2018 - Scientists use CRISPR tool to make multiple edits to DNA samples ‘in vitro’
April 23, 2018 - Knee reconstructions are on the rise among the youth in Australia
April 23, 2018 - Artificial sweeteners linked to obesity warn researchers
April 23, 2018 - CDC seeking $400 million to replace lab for deadliest germs
April 23, 2018 - Sensirion to present single-use liquid flow sensor at COMPAMED 2017
April 23, 2018 - FDA approves contact lenses that shade the sun
April 22, 2018 - Concussion recovery and symptom severity found to vary between men and women
April 22, 2018 - C. Difficile Risk Higher With Stoma Reversal Versus Colectomy
April 22, 2018 - Repeated ranibizumab doesn’t impair macular perfusion
April 22, 2018 - New microscope reveals how cells behave in 3D and real time inside living organisms
April 22, 2018 - Study shows clinical benefit and monetary gains of weight-loss surgery
April 22, 2018 - GNA Biosolutions launches world’s first Laser PCR platform at Medica Trade Fair
April 22, 2018 - Researchers present simulation model to investigate hospital responsiveness to mass casualty incidents
April 22, 2018 - Does Pot Really Dull a Teen’s Brain?
April 22, 2018 - Controversial pregnancy test drug shows deformities in zebrafish embryos within hours of exposure
April 22, 2018 - New research partnership makes childbirth safer in Mozambique
April 22, 2018 - Brief bedside visual art intervention reduces pain, anxiety in cancer patients
April 22, 2018 - The memory part of the brain may also hold clues for anxiety and depression
April 22, 2018 - AYOXXA to develop multiplex immunoassay to support treatment of sepsis patients
April 22, 2018 - New Drug Combo Ups Survival in HER2/neu Uterine Serous Cancer
April 22, 2018 - Researchers chart a new way to look at concussion
April 22, 2018 - Every parent needs to know fundamental red flags for autism
April 22, 2018 - Anatotemp expands anatomic dental implant healing abutments with 4Side anti-rotational connection
April 22, 2018 - Gene Twist Can Make Your Blood Pressure Spike From Salt
April 22, 2018 - Study suggests failed osteoarthritis drug could help treat opioid addiction
April 22, 2018 - More Americans aware of growing problem of opioid addiction
April 22, 2018 - KHN’s ‘What the Health?’ Nothing in health care ever goes away
April 22, 2018 - BGS to promote high-quality sterilization services at Health GB in Manchester
April 22, 2018 - New integrated POC tool detects biomarkers of heart failure rapidly and precisely
April 22, 2018 - Direct electrical current can be delivered to nerves for blocking pain signals
April 22, 2018 - Newly Published Phase 2 Study Found Esketamine Demonstrated Significantly Rapid Improvements in Depressive Symptoms and Suicidality
April 22, 2018 - Healthy red blood cells owe their shape to muscle-like structures
April 22, 2018 - Researchers present case study of management of rheumatic mitral regurgitation in woman contemplating pregnancy
April 22, 2018 - New black Porvair Krystal UV Quartz microplates for Circular Dichroism measurements
April 22, 2018 - Advanced flow chemistry modules enhance control of nanoprecipitation
April 22, 2018 - Look! Down in the petri dish! It’s a superplatelet!
April 22, 2018 - Research reveals why people with tetraplegia more likely to suffer from sleep apnea
April 21, 2018 - New non-invasive nerve stimulation may offer relief for people with hand tremor
April 21, 2018 - Smartphone App May Up Medication Adherence in HTN
April 21, 2018 - Western diet depletes artery-protecting immune cells
April 21, 2018 - Excelitas Technologies launches new powerful LED light source for fluorescence microscopy
April 21, 2018 - Academia and high tech companies join forces to increase production capacity for microfluidic systems
April 21, 2018 - Developing cooking skills as young adult may have long-term health benefits
April 21, 2018 - Study compares survival outcomes of different drugs for type 2 diabetes
April 21, 2018 - More Than 40 Percent of Americans Breathe Dirty Air: Report
April 21, 2018 - Obstructive sleep apnea – Genetics Home Reference
April 21, 2018 - More evidence shows exposure to traffic and outdoor air pollution increases risk of asthma
April 21, 2018 - Novel gold nanoparticle technology could guide cancer treatment in real-time
April 21, 2018 - News coverage of Ebola impacted public’s perception on disease and survivors
April 21, 2018 - S.Africa’s DIY battle against HIV
April 21, 2018 - Children with autism have gastrointestinal and immune system deregulation, research finds
April 21, 2018 - Human brain processes sight and sound in the same way, shows study
April 21, 2018 - Evolutionary history of tumor helps predict severity of prostate cancer
April 21, 2018 - Pepper plant metabolizes antibiotic in personal care products
April 21, 2018 - Tradeshow Talks with Integra
April 21, 2018 - EPFL becomes part of Chan Zuckerberg’s project to develop Human Cell Atlas
April 21, 2018 - Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy
April 21, 2018 - Breaking through the HIV vaccine ‘logjam’
April 21, 2018 - IntelliCyt introduces new QSol buffer to enable robust, consistent sampling
April 21, 2018 - Scientists publish comprehensive lineage tree of whole adult animal in Science journal
April 21, 2018 - Innovative method based on FluidFM technology could revolutionize biological research
April 21, 2018 - Americans world’s biggest TV addicts, watching four hours a day
April 21, 2018 - Investigational drug may help increase protein levels in babies with spinal muscular atrophy
April 21, 2018 - Study shows distinctions between age groups in predicting and responding to stress at home
April 21, 2018 - Aziyo Biologics, BIOTRONIK enter into US co-distribution agreement
April 21, 2018 - Opiate Use Linked to Early Mortality in IBD Patients
‘Soft’ Chemo Plus Targeted Therapy Works in HER2 Breast Cancer

‘Soft’ Chemo Plus Targeted Therapy Works in HER2 Breast Cancer

image_pdfDownload PDFimage_print

Action Points

  • Note that this randomized trial found that the addition of the somewhat “gentle” chemotherapy metronomic oral cyclophosphamide to pertuzumab and trastuzumab increased progression-free survival among older women with HER-2 positive breast cancer.
  • Be aware that these patients were all either over 70 years old, or over 60 with certain functional limitations.

A combination of “soft” chemotherapy and anti-HER2 therapy is effective in older patients with HER2-positive metastatic breast cancer and comes with an acceptable safety profile, investigators have found.

Specifically, they determined that the use of trastuzumab and pertuzumab with the “softer” chemotherapy metronomic oral cyclophosphamide provided patients with seven months longer progression-free survival compared to patients who were treated with trastuzumab and pertuzumab alone.

The study, led by Hans Wildiers, MD, PhD, University Hospitals Leuven, in Belgium, was published in The Lancet Oncology.

As pointed out by Wildiers and his colleagues, while HER2-positive metastatic breast cancer is particularly aggressive if left untreated, advances in HER2-directed drug development have resulted in improvements in outcomes.

For example, the phase 3 CLEOPATRA Trial showed that the addition of trastuzumab to pertuzumab and the chemotherapy drug docetaxel significantly improved progression-free survival, as well as overall survival.

While docetaxel combined with trastuzumab and pertuzumab has been shown to be effective in younger patients with HER2 positive metastatic breast cancer, it can be significantly toxic and affect quality of life, particularly in older patients.

The question Wildiers and his colleagues wanted to address was whether the introduction of HER2–directed therapies makes it possible to treat older HER2-positive metastatic breast cancer patients with HER2-targeted regimens and without classical therapies.

They pointed out that the dual blockade of HER2 with trastuzumab and pertuzumab has shown substantial anti-tumor activity. At the same time metronomic chemotherapy with oral cyclophosphamide has shown antitumor activity with minimal toxicity, making it more suitable for older patients.

“Given the need to develop new treatment strategies with limited toxicity for older patients with breast cancer, we aimed to examine the safety and activity of dual anti-HER2 treatment with or without metronomic chemotherapy in this population,” Wildiers and his colleagues wrote.

In this open-label, randomized, phase II trial, 80 patients were randomly assigned to receive trastuzumab and pertuzumab (TP) or TP plus metronomic oral cyclophosphamide (TPM). The patients were 70 years of age or older, or 60 years or older if they presented with certain functional limitations. The median age of the study participants was 76.7 years.

Wildiers and his colleagues found that estimated progression-free survival at 6 months was 46.2% (95% CI, 30.2-60.7) with TP alone compared to 73.4% (95% CI, 56.6-84.6) with TPM. At a median follow-up of 20.7 months, the median progression-free survival was 5.6 months (95% CI, 3.6-16.8) in the TP group versus 12.7 months (95% CI, 6.7-24.8) in the TPM group.

The most frequent grade 3-4 adverse events included hypertension (in 6 [15%] of 39 patients in the trastuzumab and pertuzumab group versus 5 [12%] of 41 in the trastuzumab and pertuzumab plus metronomic oral cyclophosphamide group), diarrhea (4 [10%] versus 5 [12%]), dyspnea (2 [5%] versus 4 [10%]), fatigue (3 [8%] versus 2 [5%]), pain (2 [5%] versus 2 [5%]), and a thromboembolic event (0 [0%] versus 4 [10%]).

In a press release Wildiers called the results “encouraging,” since he and his colleagues were able to show that the use of gentle therapy among older, frail patients could delay tumor growth while delaying or even avoiding the use of more toxic chemotherapy.

“In this age group, maintenance of [quality of life] and the avoidance of toxic side-effects may be just as important as survival,” he said.

“We believe that there is a strong case for carrying out trials designed specifically for older people,” Wildiers added. “However, financial support for such trials is very difficult to find. Additionally, older patients are far less likely to receive standard chemotherapy, and are also unlikely to be included in a randomized trial where there is a risk that they will receive a treatment with high toxicity.”

In a commentary accompanying the study, Charles E. Geyer, MD, Massey Cancer Center, Virginia Commonwealth University, also noted that while clinical trials are a prerequisite for establishing new treatment standards, “eligibility criteria generally restrict participation to fit populations with minimal comorbidities,” which, in turn, results in the underrepresentation in clinical trials of older patients with functional limitations.

Thus, Wildiers and his colleagues “are to be congratulated on their demonstration of a framework for clinical trials in older, more frail patients with HER-positive-metastatic breast cancer,” wrote Geyer.

Wildiers reports research grants from Roche and personal fees towards his institute from Roche, Amgen, Novartis, Pfizer, Puma, and Celldex. Geyer has received personal fees from Myriad and Heron Therapeutics for advisory board participation and travel support from AstraZeneca, Genentech, and Macrogenics, outside the submitted work.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2018-12-02T00:00:00-0500

last updated

Tagged with:

About author

Related Articles